Impact of metabolic syndrome on left ventricular mass in overweight and obese hypertensive subjects

International Journal of Cardiology

Volumn 121, Issue 3, 2007, Pages 267-275

  Mulè, Giuseppe ^a   Nardi, Emilio ^a   Cottone, Santina ^a   Cusimano, Paola ^a   Incalcaterra, Francesca ^a   Ester Giandalia, Maria ^a   Palermo, Alessandro ^a   Mezzatesta, Giovanni ^a   Cerasola, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Essential hypertension; Left ventricular mass; Metabolic syndrome; Obesity

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE MONITORING; BODY MASS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

BODY MASS INDEX; BODY WEIGHT; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK FACTORS;

EID: 34648852314     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.11.011     Document Type: Article

References (50)

1. Vakili B.A., Okin P.M., and Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J 141 (2001) 334-341
2. Schillaci G., Verdecchia P., Porcellati C., Cuccurullo O., Cosco C., and Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 35 (2000) 580-586
3. Schmieder R.E. The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant 20 (2005) 2610-2612
4. Lauer M.S., Anderson K.M., Kannel W.B., and Levy D. The impact of obesity on left ventricular mass and geometry: the Framingham Heart Study. JAMA 266 (1991) 231-236
5. Fox E., Taylor H., Andrew M., et al. Body mass index and blood pressure influences on left ventricular mass and geometry in African Americans: the Atherosclerotic Risk In Communities (ARIC) Study. Hypertension 44 (2004) 55-60
6. Verdecchia P., Reboldi G., Schillaci G., et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 100 (1999) 1802-1807
7. Kamide K., Nagano M., Nakano N., et al. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens 9 (1996) 1165-1171
8. Tomiyama H., Doba N., Kushiro T., et al. The relationship of hyperinsulinemic state to left ventricular hypertrophy, microalbuminuria, and physical fitness in borderline and mild hypertension. Am J Hypertens 10 (1997) 587-591
9. Lind L., Andersson P.E., Ahrén B., Hanni A., and Lithell H.O. Left ventricular hypertrophy in hypertension is associated with the insulin resistance syndrome. J Hypertens 13 (1995) 433-438
10. Quiñones Galvan A., Galetta F., Natali A., et al. Insulin resistance and hyperinsulinemia: no independent relation to left ventricular mass in humans. Circulation 102 (2000) 2233-2238
11. Rutter M.K., Parise H., Benjamin E.J., et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107 (2003) 448-454
12. Malmqvist K., Ohman K.P., Lind L., Nystrom F., and Kahan T. Relationships between left ventricular mass and the rennin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 252 (2002) 430-439
13. Chinali M., Devereux R.B., Howard B.W., et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome. (The Strong Heart Study). Am J Cardiol 93 (2004) 40-44
14. Burchfiel C.M., Skelton T.N., Andrew M.E., et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 112 (2005) 819-827
15. Mancia G., Sega R., Cesana G.C., Bombelli M., Corrao G., and Polo Friz H. Metabolic syndrome in PAMELA population: prevalence, prognostic value, out-of-office blood pressures and cardiac damage. J Hypertens 23 Suppl 2 (2005) S134
16. Cuspidi C., Meani S., Fusi V., et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 22 (2004) 1991-1998
17. Mule' G., Nardi E., Cottone S., et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 257 (2005) 503-513
18. Leoncini G., Ratto E., Viazzi F., et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med 257 (2005) 454-460
19. Mule' G., and Cerasola G. The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens (Greenwich) 8 (2006) 195-201
20. World Health Organization. Obesity - Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity (1998), World Health Organization, Geneva
21. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1053
22. Grundy S.M., Cleeman J.I., Daniel S.R., et al. Diagnosis and management of the metabolic syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
23. Sahn D.J., DeMaria A., Kisslo J., and Weiman A. The Committee on M-mode Standardization of The American Society of Echocardiography. Circulation 58 (1978) 1072-1073
24. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
25. de Simone G., Daniels S.R., Devereux R.B., et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and the impact of overweight. J Am Coll Cardiol 20 (1992) 1251-1260
26. de Simone G., Devereux R.B., Daniels S.R., Koren M.J., Meyer R.A., and Laragh J.H. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and of their capacity to predict cardiovascular risk. J Am Coll Cardiol 25 (1995) 1056-1062
27. de Simone G., Devereux R.B., Roman M.J., et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 23 (1994) 1444-1451
28. Scuteri A., Najjar S.S., Muller D.C., et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol 43 (2004) 1388-1395
29. Mule' G., Cottone S., Mongiovì R., et al. Influence of metabolic syndrome on aortic stiffness in never treated hypertensive patients. Nutr Metab Cardiovasc Dis 16 (2006) 54-59
30. Bonora E., Kiechl S., Willeit J., et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 27 (2003) 1283-1289
31. Strauss D.S. Growth-stimulatory actions of insulin in vitro and in vivo. Endocr Rev 5 (1984) 356-367
32. Holmang A., Yoshida N., Jennische E., Waldenstrom A., and Bjorntorp P. The effects of hyperinsulinaemia on myocardial mass, blood pressure regulation and central haemodynamics in rats. Eur J Clin Invest 26 (1996) 973-978
33. Andronico G., Mangano M.T., Nardi E., Mulè G., Piazza G., and Cerasola G. Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J Hypertens 11 (1993) 1097-1101
34. DeFronzo R.A., Cooke C.R., Andres R., Faloona G.R., and Davis P.J. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 55 (1975) 845-855
35. Huggett R.J., Burns J., Mackintosh A.F., and Mary D.A. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 44 (2004) 847-852
36. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest 72 (1983) 732-738
37. Patel M.B., Stewart J.M., Loud A.V., et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 84 (1991) 2091-2100
38. Schlaich M.P., Kaye D.M., Lambert E., et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108 (2003) 560-565
39. Ferri C., Pittoni V., Piccoli A., et al. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab 80 (1995) 829-835
40. Andronico G., Mangano M., Ferrara L., Lamanna D., Mulè G., and Cerasola G. In vivo relationship between insulin and endothelin: role of insulin-resistance. J Hum Hypertens 11 (1997) 63-66
41. Ferri C., Bellini C., Desideri G., et al. Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes 44 (1995) 431-436
42. Sugden P.H. An overview of endothelin signaling in the cardiac myocyte. J Mol Cell Cardiol 35 (2003) 871-886
43. Engeli S., Negrel R., and Sharma A.M. Physiology and pathophysiology of the adipose tissue rennin-angiotensin system. Hypertension 35 (2000) 1270-1277
44. Leyva F., Godsland I.F., Ghatei M., et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 18 (1998) 928-933
45. Nickola M.W., Wold L.E., Colligan P.B., Wang G.J., Samson W.K., and Ren J. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 36 (2000) 501-505
46. Rajapurohitam V., Gan X.T., Kirshenbaum L.A., and Karmazyn M. The obesity associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 93 (2003) 277-279
47. Barouch L.A., Berkowitz D.E., Harrison R.W., O'Donnell C.P., and Hare J.M. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108 (2003) 754-759
48. Tajmir P., Ceddia R.B., Li R.K., Coe I.R., and Sweeney G. Leptin increases cardiomyocytes hyperplasia via extracellular signal-regulated kinase and phosphatidylinositol 3 kinase dependent signaling pathways. Endocrinology 145 (2004) 1550-1555
49. Paolisso G., Tagliamonte M.R., Galderisi M., et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 34 (1999) 1047-1052
50. Perego L., Pizzocri P., Corradi D., et al. Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy. J Clin Endocrinol Metab 90 (2005) 4087-4093